- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ONCODESIGN PRECISION MEDICINE Aktie jetzt für 0€ handeln | |||||
| Fr | Oncodesign Precision Medicine Reacquires Rights to Its OPM-201 Program From Servier After a Positive Phase I Trial in Healthy Volunteers | 226 | Business Wire | Retrieval by OPM of all rights to the OPM-201 program and associated patent portfolio Confirmation of the molecule's safety in healthy volunteers
Regulatory News:
Oncodesign Precision... ► Artikel lesen | |
| 22.10. | Oncodesign Precision Medicine: OPM Reports Final Results of Its Phase 1 Study With RIPK2 Inhibitor OPM-101, With Strong Safety Data and No Cardiac Toxicity, Paving the Way for the Launch of Phase 1b/2a | 263 | Business Wire | Finalization of the study report on the double-blind, placebo-controlled Phase 1 trial of OPM-101 in 104 healthy volunteers (HV) who received OPM-101 24-hour ECG analysis reveals no toxic... ► Artikel lesen | |
| 15.10. | Oncodesign Precision Medicine: OPM Announces Poster Presentation on OPM-101, a RIPK2 Kinase Inhibitor, in Healthy Volunteers at UEG Week 2024 Conference | 225 | Business Wire | Presentation by Professor Laurent Peyrin-Biroulet (M.D., PhD Professor of Gastroenterology at CHRU of Nancy) and Bruno Robin (PharmD, Head of OPM Clinical Development) of safety, pharmacokinetic... ► Artikel lesen | |
| 25.09. | Oncodesign Precision Medicine: OPM Announces Its First-half 2024 Results and Provides an Update on Its Clinical Developments, and Its Financial Situation | 253 | Business Wire | OPM-101 successfully completed its Phase 1 trial with healthy volunteers, enabling the company to anticipate the start of a Phase 1b/2a clinical trial in 2024/early 2025. OPM-201, licensed... ► Artikel lesen | |
| 16.07. | Oncodesign Precision Medicine: OPM Announces Positive Results of Its Phase 1 in Healthy Volunteers with OPM-101: Strong Target Engagement With Excellent Safety Profile | 247 | Business Wire | End of double-blind, placebo-controlled phase 1 trial with OPM-101: 104 healthy volunteers (VS) participated in this trial designed to assess the safety of OPM-101 in humans Very good safety... ► Artikel lesen | |
| 15.05. | Oncodesign Precision Medicine and Navigo Proteins GmbH Sign a Strategic Collaboration Agreement for the Research and Development of New Systemic Radiotherapy Agents | 311 | Business Wire | Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic... ► Artikel lesen | |
| 18.04. | Degroof Petercam Initiates Coverage of Oncodesign Precision Medicine | 604 | Business Wire | Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic... ► Artikel lesen | |
| 17.04. | Oncodesign Precision Medicine (OPM) obtains €5.6 million in public funding for its DEMOCRITE program dedicated to the clinical development of OPM-101 | 407 | Business Wire | DEMOCRITE Project: Demonstrating the efficiency of OPM-101 by targeting RIPK2 in Inflammatory Bowel Disease
Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic:... ► Artikel lesen | |
| 26.03. | Oncodesign Precision Medicine: OPM Publishes Its Annual Results for 2023 and Provides an Update on Its Clinical Developments | 369 | Business Wire | R&D investment up 27% to €8.8 M, mainly linked to the clinical development of OPM-101 and the start of a preclinical program in oncology OPM-102 Cash position of €10 M on December the... ► Artikel lesen | |
| 29.02. | Oncodesign Precision Medicine Obtains Deep Tech Development Funding for Its ANIMUS Program | 466 | Business Wire | ANIMUS program: development of proprietary methods using AI to optimize molecules derived from our Nanocyclix® technology, for faster selection of drug candidates
Regulatory News:
Oncodesign... ► Artikel lesen | |
| 25.01. | Oncodesign Precision Medicine receives ERDF fund totalling €2.1 M for its COMETE program | 459 | Business Wire | Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM) (Paris:ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 17,400 | -2,68 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
| QIAGEN | 42,900 | +0,04 % | Biotech Report: Evotec klettern, Qiagen leichter | (shareribs.com) Frankfurt / New York 16.12.2024 - Die Biotech-Aktien zeigten sich im deutschen Handel uneinheitlich. Für Evotec ging es nach oben, während Qiagen und auch Biontech korrigierten. An der... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 76,52 | +5,05 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome | Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the third Rare Pediatric Disease Designation for relutrigine, adding to those... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 14,990 | +6,24 % | Arcutis Biotherapeutics, Inc.: Arcutis Submits ZORYVE (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis | ZORYVE cream 0.05% provided meaningful disease clearance and rapid reduction in itch in pivotal trialsRoflumilast cream was well tolerated and demonstrated a favorable safety and tolerability profile... ► Artikel lesen | |
| EVOTEC | 8,405 | +1,08 % | Evotec-Aktie: Geht es jetzt weiter bergab - oder kommt doch noch in Kürze der große Durchbruch? Wir analysieren und verraten Ihnen unsere Tradingidee! | © Foto: SymbolbildWas passiert mit Evotec? Die Aktie des Hamburger Biotech-Unternehmens hatte 2024 kein einfaches Jahr: Fast 60 Prozent Kursverlust, Gerüchte über eine Übernahme und die Rückkehr in... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,340 | -0,27 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| CELCUITY | 12,460 | +3,83 % | Celcuity Inc.: Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium | Median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-naïve in the advanced setting was 77.3 months Median OS among patients previously treated with... ► Artikel lesen | |
| CONTINEUM THERAPEUTICS | 13,500 | +1,12 % | Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that... ► Artikel lesen | |
| BIONTECH | 108,60 | +0,09 % | Abstieg und Hoffnung: So steht es um den BioNTech-Konkurrenten Moderna | Die Aktie von Moderna hat in den vergangenen zwölf Monaten eine enttäuschende Entwicklung hingelegt. Im Nasdaq 100 gehört sie in diesem Zeitraum zu den zwei schlechtesten Werten. Nun muss sie den Index... ► Artikel lesen | |
| HUMACYTE | 4,635 | +33,77 % | Pre-market Movers: My Size, Nvni Group, Psyence Biomedical, Humacyte, PainReform | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.55 A.M. ET).In the Green My Size, Inc. (MYSZ) is up over 372% at $6.43.
Nvni... ► Artikel lesen | |
| AMGEN | 252,90 | +0,18 % | What's Going On With Amgen Stock On Friday? | ||
| JANUX THERAPEUTICS | 56,70 | -0,09 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| FOGHORN THERAPEUTICS | 5,140 | +3,21 % | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities | Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in combination with decitabine in patients with relapsed and/or refractory AML; efficacy... ► Artikel lesen | |
| IMMUNOVANT | 25,880 | +0,86 % | Immunovant (NASDAQ:IMVT) Trading Down 5.2% - Here's Why | ||
| RECURSION PHARMACEUTICALS | 6,035 | -0,90 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen |
Das Unternehmen ONCODESIGN PRECISION MEDICINE SA kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,050 (-5,41 %) liegt der Kurs bei 0,874 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONCODESIGN PRECISION MEDICINE SA finden Sie auf Wallstreet Online.
